The results of the research on the effects of Earstim on the motor skills of Parkinson’s patients were published in an article in October 2020 in the Frontiers in Human Neuroscience journal. Please click here to access the article.
A pre-application meeting was held with the FDA officials in February 2020 at the Administration’s offices to discuss the use of Earstim in clinical trials in the USA and its commercialization.
The results of the research on the effects of Earstim on the motor skills of Parkinson’s patients were explained in a poster presentation at the World Parkinson Congress 2019 in Kyoto, Japan.
Following the positive results from the pilot clinical trials, Stoparkinson Healthcare Systems, LLC was incorporated in January 2019 in the USA to commercialize Earstim.
Stoparkinson will partner with Parkinson Study Group, a non-profit group of physicians and other scientists dedicated to clinical research of Parkinson’s disease, for a multi-center pilot clinical trial in the USA.